Recruiting

How well two targeted melanoma drugs work in real-world care

Plain-English translation of NCT04045691 on ClinicalTrials.gov ↗ · Source last updated January 2021 · Translation generated June 2026 · How we translate trials

What is this trial?

This is a real-world study that tracks how well plus work for people with advanced melanoma that has a specific genetic mutation (called BRAF V600). Instead of testing the medication in a controlled lab setting, researchers are collecting information from patients like you who are already taking this treatment through their regular doctor appointments—so they can understand how it performs and affects quality of life in everyday care.

Doctors know these two drugs work well in controlled trials, but they want to understand how this treatment performs when used by real patients in actual hospitals and clinics across Germany, Austria, and Switzerland. This study will help doctors learn more about long-term benefits, side effects, and how to best support patients taking this medication.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you have been diagnosed with advanced or metastatic melanoma with a BRAF V600 mutation
you have either never received prior treatment for your melanoma, or you have received only one prior line of immunotherapy (checkpoint inhibitor treatment)
your doctor has already decided to treat you with encorafenib plus binimetinib according to standard prescribing guidelines, independent of this study
you are willing to provide written consent for your medical data to be documented and shared for research purposes

You likely don't qualify if…

you have previously received a BRAF or MEK inhibitor medication (unless it was given as a preventive treatment more than 6 months ago and has been stopped)
you have received more than one line of immunotherapy for your advanced melanoma
you have received chemotherapy for your melanoma
you are currently enrolled in another clinical trial that involves testing a new intervention
you are currently being treated for a different type of cancer at the same time

What participation looks like

You will continue taking your prescribed medication as normal through your regular doctor. Researchers will collect information from your medical visits and records to document how you respond to the treatment, any side effects, and how it affects your daily life and quality of life. This is a non-interventional study, meaning your doctor decides on your treatment—the research team simply gathers and reviews the information from your standard care visits over time.

AI-generated summary from trial data · Jun 7, 2026 · Not medical advice

Trial locations(59 sites)

Austria

11, Graz

13, Innsbruck

14, Klagenfurt

10, Linz

3, Linz